Home › Trial NCT04666259
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
- Trial IDNCT04666259
- StatusCompleted
- PhasePhase 3
- Study typeInterventional
- SponsorNovartis Pharmaceuticals
- Enrollment56
- Start date2021-05-25
- ConditionsChronic Myelogenous Leukemia - Chronic Phase
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.